Cartesian Therapeutics, Inc. (RNAC)
RNAC Stock Price Chart
Explore Cartesian Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RNAC price movements and trends.
RNAC Company Profile
Discover essential business fundamentals and corporate details for Cartesian Therapeutics, Inc. (RNAC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
22 Jun 2016
Employees
66.00
Website
https://selectabio.comCEO
Carsten Brunn
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Financial Timeline
Browse a chronological timeline of Cartesian Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.81.
Earnings released on 7 Aug 2025
EPS came in at $0.50 surpassing the estimated -$0.76 by +165.79%, while revenue for the quarter reached $298.00K , beating expectations by +67.83%.
Earnings released on 8 May 2025
EPS came in at -$0.68 falling short of the estimated -$0.61 by -11.48%, while revenue for the quarter reached $1.10M , beating expectations by +60.00%.
Earnings released on 20 Mar 2025
EPS came in at -$0.59 surpassing the estimated -$0.78 by +24.36%, while revenue for the quarter reached -$759.00K , missing expectations by -175.90%.
Earnings released on 7 Nov 2024
EPS came in at -$0.69 surpassing the estimated -$0.78 by +11.54%, while revenue for the quarter reached $387.00K , beating expectations by +238.61%.
Earnings released on 8 Aug 2024
EPS came in at $0.54 surpassing the estimated -$1.07 by +150.47%, while revenue for the quarter reached $33.45M , beating expectations by +1.22K%.
Earnings released on 8 May 2024
EPS came in at -$1.97 falling short of the estimated -$0.81 by -143.21%, while revenue for the quarter reached $5.84M , beating expectations by +250.40%.
Stock split effective on 5 Apr 2024
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Mar 2024
EPS came in at -$2.40 falling short of the estimated -$0.30 by -700.00%, while revenue for the quarter reached $8.27M , beating expectations by +40.82%.
Earnings released on 13 Nov 2023
EPS came in at -$2.40 falling short of the estimated -$2.10 by -14.29%, while revenue for the quarter reached $6.55M , missing expectations by -9.39%.
Earnings released on 17 Aug 2023
EPS came in at -$0.07 surpassing the estimated -$0.09 by +22.22%, while revenue for the quarter reached $5.25M , missing expectations by -6.27%.
Earnings released on 31 Mar 2023
EPS came in at -$0.17 surpassing the estimated -$2.60 by +93.48%, while revenue for the quarter reached $5.94M , missing expectations by -51.08%.
Earnings released on 30 Dec 2022
EPS came in at $0.05 surpassing the estimated -$2.17 by +102.13%, while revenue for the quarter reached $16.80M , beating expectations by +43.74%.
Earnings released on 29 Sept 2022
EPS came in at -$0.06 surpassing the estimated -$0.17 by +63.85%, while revenue for the quarter reached $20.71M , missing expectations by -17.86%.
Earnings released on 29 Jun 2022
EPS came in at $0.07 surpassing the estimated -$2.27 by +103.06%, while revenue for the quarter reached $39.27M , beating expectations by +184.97%.
Earnings released on 30 Mar 2022
EPS came in at $0.27 , while revenue for the quarter reached $34.00M .
Earnings released on 30 Dec 2021
EPS came in at $0.12 surpassing the estimated -$3.35 by +103.53%, while revenue for the quarter reached $29.94M , beating expectations by +146.62%.
Earnings released on 29 Sept 2021
EPS came in at -$0.19 , while revenue for the quarter reached $24.43M .
Earnings released on 29 Jun 2021
EPS came in at $0.05 , while revenue for the quarter reached $19.66M .
Earnings released on 30 Mar 2021
EPS came in at -$0.27 , while revenue for the quarter reached $11.05M .
Earnings released on 31 Dec 2020
EPS came in at -$0.17 , while revenue for the quarter reached $11.95M .
Earnings released on 30 Sept 2020
EPS came in at -$0.11 , while revenue for the quarter reached $4.65M .
RNAC Stock Performance
Access detailed RNAC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.